ReviewEuropean journal of medical research2025
ROS-mediated cell death and phase separation in gynecological malignancies.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of cuproptosis and its application in inflammatory bowel disease (Review).International journal of molecular medicine · 2026Review
- On the Edge of Benefit and Harm: Reactive Oxygen Species in Cancer.International journal of molecular sciences · 2026Review
- Mitochondrial Long Non-Coding RNAs in Gynecological Cancers: Pathogenic Signaling Pathways and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- Impact of oxidative stress on malignant tumor progression and emerging therapeutic strategies.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) are reactive products of cellular metabolism that, under physiological conditions, activate specific signaling pathways essential for cellular functions. Excessive accumulation of ROS overwhelms cellular antioxidant defenses, leading to functional damage or cell death. ROS-mediated cell death manifests in multiple forms, including apoptosis, ferroptosis, immunogenic cell death, pyroptosis, oxeiptosis, NETosis, and parthanatos. In gynecological malignancies, inducing ROS-mediated cell death is proposed as a therapeutic strategy. Furthermore, research indicates that excessive ROS promotes abnormal phase separation, resulting in functional damage to tumor cells. Therefore, ROS-mediated cell death and phase separation provide a new entry point for preventing tumorigenesis or treating gynecological malignancies. In this review, we summarize the mechanisms underlying ROS-mediated cell death and phase separation, and describe innovative strategies based on ROS that hold promise for treating gynecological malignancies. This review will also discuss controversial issues in tumor therapeutics, including the paradoxical roles of ROS manipulation. This will offer new insights into the management of gynecological malignancies, providing theoretical support for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.